A successful phase IIb trial testing the power of Restorbio Inc.'s oral TORC1 inhibitor to prevent respiratory tract infection (RTIs) in high-risk elderly patients has put it on track to complete a pivotal phase III program in 2019 and a new drug application in 2020, assuming all goes well. Top-line results of the study showed that, relative to placebo, RTB-101 reduced the percentage of patients with one or more lab-confirmed RTIs by nearly a third during a 16-week window, an outcome that drove company shares (NASDAQ:TORC) 49.5 percent higher to close at $13.47.